Dr. Hulme has built and run several high-throughput medicinal chemistry organizations in industry and transitioned to an academic role in late 2007. He has managed portfolios of targets spanning the value chain in drug discovery from hit generation to progression of molecules into man and as such managed teams that produced early development candidates for PDEIV (Rhone-Poulenc Rorer) and VR-1 (Amgen). In total, it is estimated that 60+ targets of interest have passed through his organizations, spanning a multitude of therapeutic areas that include oncology, metabolic disorders, inflammation, pain, and neurodegeneration.
As Director of BIO5 Medicinal Chemistry, Dr. Hulme has the resources and extensive infrastructure in place to initiate and significantly progress the translational campaign. More specifically, CNS projects previously falling under his jurisdiction include the development of inhibitors of JNK-3 for stroke (Amgen), MCHr for obesity (Amgen), Pyk-2 for the treatment of brain gliomas (University of Arizona) and BACE for Alzheimer’s (Lilly). A significant number of other kinases were also part of prior industrial portfolios he ran, including JNK-1, PKB, Aurora A/B and Plk-1, and preliminary collaborations at the University of Arizona and Yale include targeting Plk-4, ROCK and aPKC. Indeed, the Phe is well versed in addressing the need for molecular pre-requisite physico-chemical properties that enable passive BBB penetration and minimization of residence time in the BBB lipid bi-layer to dial out potential pGP efflux liabilities.
Dr. Hulme has been involved in kinase research for ~ 20 years, being a co-author on one of the very early medicinal chemistry reviews in the field. The DYRK1A collaboration with Dr. Travis Dunckley has been active for more than three years although needs sustained funding to build on the significant progress to date. Recent reviews by the collaborators detail the state-of-art relevance of the target and current inhibitor design, and emerging indications for Glioblastoma are being investigated. In short, he is extremely qualified to pursue members of the kinase target-family in the neurodegeneration field and this is supplemented by his national/international reputation in high-throughput medicinal chemistry and file enhancement arenas.
1996–1997 Senior Research Scientist, Rhone-Poulenc Rorer, Collegeville, PA.
1997–1998 Research Fellow, Rhone-Poulenc Rorer, Collegeville, PA.
1999–2004 Head of High-Throughput Medicinal Chemistry, Amgen, Thousand Oaks, CA.
2004–2007 Head of High-Throughput Medicinal Chemistry, Eli Lilly, Indianapolis, IN.
2007–2010 Associate Professor, University of Arizona, Tucson, AZ.
2010–Present Professor Medicinal Chemistry, University of Arizona, Director BIO5 Medicinal Chemistry Tucson, AZ.
2011 University of Arizona Leading Edge Researcher 2011.
2007–2008 Abbott Laboratories New Faculty Award for Creativity in Organic Chemistry.
2006 Lilly Award for Excellence in File Enhancement.
2015 ANR Grant Reviewer
2014-Present Editorial Board Member “Central Nervous System Agents in Medicinal Chemistry”
2014 University of Kansas KOBRE Drug Discovery Grant External Reviewer.
2012–2014 NWO Grant Reviewer.
2012 Host & Chair, ACS National Medicinal Chemistry Conference, Oro Valley, AZ
2011 R19 study section.
2011 Editor: Special Edition on Multi-Component reactions, MODI.
2010 Ad hoc Special Emphasis Panel (P01 grant renewals).
2009 Session Chair. Mastering Medicinal Chemistry, Feb’ 25-27, San Francisco.
2009 SBIR Study Section, October 2009, 2010.
2009 Member External Advisory Board, SPORE lung cancer initiative, University of Louisville.
2008 Synthetic and Biological Chemistry B Study Section, October 2008.
2008 Member of Special Emphasis Panel July 2008: NIH renewals for “Centers of Excellence in Chemical Methodologies and Library Development (CMLD).”
2007–2011 Associate Editor, Molecular Diversity.
2007-Present Arizona Bioindustry Association (AZBio) member.
2007-Present AACP Member (American Association of Colleges of Pharmacy).
2005 Member Study Section P41 Pilot Scale Libraries.
2004–2011 IUPAC Affiliate Member.
2003-Present Editorial Advisory Boards of Current Organic Synthesis/ARKIVOC/Open Drug Discovery.
1999-Present ACS member (American Chemical Society).
1997-Present Ad hoc reviewer for more than 30 journals.